Latest News About - Gastroenteric Syndrome

 
Show/hide duplicate news articles.
Filter by countryfromabout
<<10<12345678910>>>10
 
Show/hide duplicate news articles.
<<10<12345678910>>>10

Tools

Load latest edition

Wednesday, November 14, 2018

6:12:00 PM CET

Subscribe
RSS | MAP

Language Selection

For any category/filter, users can choose:

  1. the language of the categorized news items (e.g. fr and de to display only those news items in French and German)
  2. the language of the user interface (e.g. it for Italian)

In Top Stories, the user can display the largest clusters of news items for one language only (e.g. en shows all clusters in English)

Country Selection

Users can choose:

  1. country mentioned in the news item (articles about a country)
  2. country in which the news item was published (articles from a country)

Languages Collapse menu...Expand menu...Open help...

Select your languages

ar
az
be
bg
bs
ca
cs
da
de
el
en
eo
es
et
fa
fi
fr
ga
ha
he
hi
hr
hu
hy
id
is
it
ja
ka
km
ko
ku
ky
lb
lo
lt
lv
mk
ml
mn
ms
mt
nl
no
pap
pl
ps
pt
ro
ru
rw
se
si
sk
sl
sq
sr
sv
sw
ta
th
tr
uk
ur
vi
zh
all
Show additional languagesHide additional languages

Interface:

Most reported countries (24h)

Theme countries

AlertLevel (24h)

Alert level graph

 Previous 14 days average

Alert level:
 high   medium   low

Quotes... Extracted quotes

Roy Baynes said: “In this pivotal trial, KEYTRUDA resulted in a statistically significant and clinically meaningful improvement over standard chemotherapy in overall survival for patients with advanced esophageal or esophagogastric junction carcinoma whose tumors express PD-L1 with a CPS of 10 or greater. This marks the sixth tumor type where KEYTRUDA has demonstrated a survival benefit, and represents the first time an anti-PD-1 therapy has achieved overall survival for this patient population,” External link

marketwatch Wednesday, November 14, 2018 1:11:00 PM CET

Sandra Horning said: “Tecentriq in combination with nab -paclitaxel has the potential to meaningfully advance treatment for people with PD-L1-positive, metastatic triple-negative breast cancer. People need more options for this type of breast cancer, which is particularly difficult to treat,” External link

marketwatch Tuesday, November 13, 2018 7:19:00 AM CET

John Seymour säger: – Patienter med kronisk lymfatisk leukemi kan få återfall och bli refraktära mot första linjens behandling, och det finns behov av bättre behandlingsalternativ för dessa patienter som annars har begränsade behandlingsmöjligheter, External link

onkologiisverige Monday, November 5, 2018 11:45:00 AM CET

John Seymour säger: – Kombinationen venetoklax plus rituximab erbjuder dessa patienter ett behandlingsalternativ som är bättre än en typ av kemoimmunterapi, och som kan ge djupa behandlingssvar, vilket visas av andelen MRD-negativitet mätt i perifert blod och benmärg, vilket ger möjlighet till en fast behandlingstid utan behov av kemoimmunterapi, External link

onkologiisverige Monday, November 5, 2018 11:45:00 AM CET

Michael Severino säger: – Godkännandet av Venclyxto i kombination med rituximab är ett viktigt steg framåt för att ge patienter som fått återfall eller har behandlingsrefraktär KLL en chans att leva längre utan att bli försämrade i sin sjukdom, External link

onkologiisverige Monday, November 5, 2018 11:45:00 AM CET

Michael Severino säger: – Samtidigt fortsätter vi med vår forskning för att ta fram terapier som har potential att utveckla och förbättra standardbehandlingen vid blodcancer, External link

onkologiisverige Monday, November 5, 2018 11:45:00 AM CET

Panos Kammenos заяви: „Ще сътрудничим и ще останем в правителството до последно“ External link

focus-news Wednesday, October 24, 2018 5:23:00 AM CEST

Şener Elcil dedi: “Amacımız toplumsal bütünlük çerçevesinde işveren, işadamı, işçi, akademisyen herkesin elini taşın altına koyarak ortak bir çıkış noktası bulmak ve bu doğrultuda beraber çalışarak toplumumuzun dinamikleri ile beraber daha gelişmiş, kendi ayakları üzerinde duran bir Kıbrıs Türk toplumu yaratmaktır” External link

yeniduzen Friday, August 17, 2018 11:47:00 AM CEST

Most associated names

Daily number of articles in this category

Trend data not available for this selection.